NovaBridge Biosciences (NBP) Accounts Payables (2018 - 2025)

NovaBridge Biosciences (NBP) has reported Accounts Payables for 8 consecutive years, with $16.8 million the latest figure, recorded in Q4 2025.

• Quarterly Accounts Payables rose 123.35% year-over-year to $16.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $16.8 million (up 123.35% YoY) and the FY2025 annual result came in at $16.8 million, up 123.35% from the prior year.
• Accounts Payables climbed to $16.8 million in Q4 2025 per NBP's latest filing, from $15.2 million in the prior quarter.
• Over the last five years, Accounts Payables for NBP reached as high as $92.8 billion in Q4 2021 and fell as low as $6.5 million in Q2 2025.
• A 5-year average of $7.2 billion and a median of $16.8 million in 2025 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2021 — Accounts Payables surged 109616.73% — and 2022, when it slumped 99.89%.
• Year by year, Accounts Payables stood at $92.8 billion in 2021, then slumped by 99.89% to $99.3 million in 2022, then sank by 49.99% to $49.7 million in 2023, then slumped by 84.84% to $7.5 million in 2024, then jumped by 123.35% to $16.8 million in 2025.
• According to Business Quant data, Accounts Payables over the past three periods registered $16.8 million, $15.2 million, and $6.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.